#United States #Trulieve Cannabis #Tallahassee #medical cannabis #NYSE TRLV

Trulieve Reports Strong Q2 2026 Results

Overview
On August 7, 2026, Trulieve Cannabis Corp. (NYSE: TRLV), a premier medical cannabis company in the United States, announced its financial results for the second quarter ending June 30, 2026. The results are substantial, indicating Trulieve's robust position in a burgeoning industry. This release focuses on the company's financial performance and strategic developments in the increasingly competitive cannabis market.

Financial Highlights

In the second quarter of 2026, Trulieve achieved impressive metrics:

• - Revenue: $271 million, driven predominantly by retail sales, which constituted 94% of total revenue.
• - Gross Profit: The company reported a gross profit of $162 million, reflecting a gross margin of 60%. This was slightly lower than the previous year's margin of 61%, showcasing a resilient cost management approach amid fluctuating market conditions.
• - Net Loss: Despite the revenue growth, Trulieve experienced a net loss attributable to common shareholders of $406 million, equating to $2.10 per share. This figure includes the $407 million impact from the deconsolidation of its subsidiary, Harvest. Conversely, adjusted net income for this quarter stood at $20 million or $0.11 per share.
• - Adjusted EBITDA: The company achieved an adjusted EBITDA of $98 million, indicating healthy operational performance with 36% of revenue translating to EBITDA.

The company’s operational cash flow for the quarter was recorded at $53 million, and it produced a free cash flow of $32 million, showcasing a healthy operational basis. As of the end of June, Trulieve held $325 million in cash, positioning itself well for future investments and operational enhancements.

Strategic Developments

Trulieve is not only focusing on financial metrics but is also actively engaging in strategic initiatives:

• - Deconsolidation of Harvest: Following the deconsolidation of Harvest on June 3, 2026, Trulieve has transitioned to focus solely on its own medical operations, fostering a streamlined approach to its business.
• - Expanded Retail Footprint: The company launched four new dispensaries located in Belleview, Boca Raton, Lutz, and Tallahassee, Florida, enhancing its retail presence significantly. This aligns with their goal to expand access to medical cannabis in various markets, particularly with the ongoing medical cannabis program expansion in Georgia and a focused growth strategy in Texas.
• - Listing on NYSE: Trulieve made history by being the first U.S. cannabis company to be listed on the New York Stock Exchange under the ticker TRLV, a milestone that enhances its visibility and access to capital.

Future Outlook

Kim Rivers, Trulieve's CEO, expressed optimism about the future: “With broader cannabis rescheduling and state program expansions in markets like Georgia and Texas on the horizon, Trulieve is well positioned to leverage its scale, financial strength, and branded products to drive future growth.” The company is strategically positioned for further growth, especially with its focus on quality branded products and expanding operational capabilities.

Conclusion
The financial outlook for Trulieve remains robust as it navigates the competitive cannabis landscape. The combination of solid revenue growth, strategic expansion, and ongoing market demand positions the company for continued success. As legal frameworks for cannabis evolve, Trulieve is poised to capitalize on new opportunities, making it a significant player in the industry. The company has built a firm foundation with its innovative products and unparalleled customer service, aiming to expand access to cannabis products while ensuring long-term shareholder value.

For more updates and detailed financial statements, visit Trulieve's investor relations page.

• ---

This article was prepared based on Trulieve's press release dated August 7, 2026. All figures are in USD and reported in accordance with GAAP guidelines.